Text Modules

Share

Program Content

  • ICI in Early TNBC
    Immune Checkpoint Inhibition in Early-Stage TNBC
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2022

    Expires: September 14, 2023

    View Activity
  • Key Trials in HR+/HER2- EBC
    Key Ongoing Clinical Trials in HR-Positive/HER2-Negative Early-Stage Breast Cancer
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • Adjuvant Olaparib in HER2- EBC
    Germline BRCA Testing and Targeting With Adjuvant Olaparib in HER2- EBC
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 17, 2022

    Expires: May 16, 2023

    View Activity
  • Adj Abemaciclib HR+/HER2- EBC
    Risk Assessment and Ki-67 Testing in HR-Positive/HER2-Negative EBC for Adjuvant Abemaciclib
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 12, 2022

    Expires: May 11, 2023

    View Activity
  • Biomarkers in HER2-Negative EBC
    Overview of Risk Assessment and Biomarker Testing to Inform Treatment in HER2-Negative Early Breast Cancer
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 06, 2022

    Expires: April 05, 2023

    View Activity

Faculty

cover img faculity

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

cover img faculity

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

ProCE Banner

Supporters

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner